Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV preventive vaccines. Progress to date

J Esparza1, S Osmanov, W L Heyward

  • 1Global Programme on AIDS, World Health Organization, Geneva, Switzerland.

Drugs
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Treatment of adolescent varicocele: is percutaneous embolization better?].

Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica·2009
Same author

Purely intramedullary spinal cord primitive neuroectodermal tumor: case report and review of the literature.

Neurocirugia (Asturias, Spain)·2009
Same author

Recurrent meningitis and persistence of craniopharyngeal canal: case report.

Neurocirugia (Asturias, Spain)·2009
Same author

Surgical treatment of isolated and syndromic craniosynostosis. Results and complications in 283 consecutive cases.

Neurocirugia (Asturias, Spain)·2008
Same author

[Radiation exposure in children undergoing diagnostic imaging: a study of Pamplona County].

Radiologia·2008
Same author

[Positional plagiocephaly. Diagnosis and treatment].

Neurocirugia (Asturias, Spain)·2007
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Developing effective HIV vaccines remains challenging due to unknown protective immune responses and HIV's genetic diversity. Current candidate vaccines show promise but require further large-scale human trials to assess efficacy.

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Identifying immune correlates of protection against HIV infection is crucial for vaccine development.
  • HIV's genetic variability presents a significant hurdle for creating broadly effective vaccines.
  • Studies on natural HIV resistance and long-term non-progressors offer insights for vaccine design.

Purpose of the Study:

  • To review the current state of HIV vaccine development, including challenges and promising strategies.
  • To discuss the evaluation of first and second-generation HIV vaccine candidates.
  • To outline the next steps and complexities involved in advancing HIV vaccine trials.

Main Methods:

  • Evaluation of subunit recombinant envelope (gp120/gp160) vaccines in animal models and human trials (Phase I/II).

Related Experiment Videos

  • Assessment of live recombinant vector (e.g., poxvirus) vaccines, including boosting with subunit vaccines, in early human trials (Phase I).
  • Review of challenges and requirements for future large-scale efficacy trials (Phase II/III).

    • Main Results:

    • Subunit vaccines are well-tolerated, induce neutralizing antibodies in humans, and protected chimpanzees, but not cytotoxic T lymphocytes.
    • Recombinant vector vaccines show potential for inducing both humoral and cell-mediated immunity, but protection data in chimpanzees is unavailable.
    • Candidate vaccines require progression to complex, collaborative Phase II and III trials to determine human efficacy.

    Conclusions:

    • Significant challenges remain in HIV vaccine development, primarily concerning immune response correlates and viral diversity.
    • Current vaccine candidates, including subunit and recombinant vector approaches, have demonstrated safety and induced immune responses.
    • Careful planning and extensive collaboration are essential for the successful execution of future large-scale human efficacy trials.